Ali Bukhari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ali Bukhari has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
Aaron P. Rapoport
University of Maryland Medical Center Baltimore Maryland USA
5 shared publications- Saurabh Dahiya
Department of Medicine, University of Maryland School of Medicine and Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA
5 shared publications Jean Yared
University of Maryland Medical Center Baltimore Maryland USA
4 shared publicationsNancy Hardy
University of Maryland Medical Center Baltimore Maryland USA
4 shared publications- Forat Lutfi
Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS 66205, USA
3 shared publications Kathleen Ruehle
Marlene and Stewart Greenebaum Comprehensive Cancer Center University of Maryland Baltimore Maryland USA
3 shared publications
Latest Publications
- 12 May 2026
- Published by Wiley in European Journal of Haematology
- Vol. 117 (4) , 936-942
Real‐World Experience With a ZUMA ‐1 Cohort 4 Adopted Approach to CRS and ICANS in CAR ‐T Recipients
Axicabtagene ciloleucel (Axi‐cel) is a chimeric antigen receptor T‐cell (CAR‐T) therapy approved for the treatment of relapsed/refractory (R/R) large B‐cell lymphoma (LBCL). The registrational phase 1/2 ZUMA‐1 study cohorts 1 and 4 addressed toxicity management in terms of cytokine release syndrome (CRS) and immune effector cell‐associated neurotoxicity syndrome (ICANS) whereby tocilizumab and corticosteroids were deployed earlier in cohort 4. In this real‐world, single‐institution study of 119 patients receiving Axi‐cel CAR‐T therapy for R/R LBCL with 70 in cohort 1 and 49 in cohort 4, we demonstrate significantly less toxicity, intensive care unit (ICU) utilization, and cumulative steroid use with an early intervention strategy. Laboratory parameters and comorbidities did not significantly differ between groups except for a higher incidence of renal insufficiency in the cohort 4 group (28.6% vs. 4.3%, p < 0.01). The maximum grade CRS was significantly lower for cohort 4 versus 1 (1 vs. 2, p < 0.01). Furthermore, cumulative corticosteroid use was significantly less in the cohort 4 early intervention group (110 mg vs. 190 mg dexamethasone equivalents). These favorable findings did not have a deleterious impact on outcomes and efficacy with similar overall response rate, progression‐free survival, and overall survival with both toxicity management approaches.
- 12 May 2026
- Published by Wiley in European Journal of Haematology
- Vol. 117 (4) , 936-942
Real‐World Experience With a ZUMA ‐1 Cohort 4 Adopted Approach to CRS and ICANS in CAR ‐T Recipients
Axicabtagene ciloleucel (Axi‐cel) is a chimeric antigen receptor T‐cell (CAR‐T) therapy approved for the treatment of relapsed/refractory (R/R) large B‐cell lymphoma (LBCL). The registrational phase 1/2 ZUMA‐1 study cohorts 1 and 4 addressed toxicity management in terms of cytokine release syndrome (CRS) and immune effector cell‐associated neurotoxicity syndrome (ICANS) whereby tocilizumab and corticosteroids were deployed earlier in cohort 4. In this real‐world, single‐institution study of 119 patients receiving Axi‐cel CAR‐T therapy for R/R LBCL with 70 in cohort 1 and 49 in cohort 4, we demonstrate significantly less toxicity, intensive care unit (ICU) utilization, and cumulative steroid use with an early intervention strategy. Laboratory parameters and comorbidities did not significantly differ between groups except for a higher incidence of renal insufficiency in the cohort 4 group (28.6% vs. 4.3%, p < 0.01). The maximum grade CRS was significantly lower for cohort 4 versus 1 (1 vs. 2, p < 0.01). Furthermore, cumulative corticosteroid use was significantly less in the cohort 4 early intervention group (110 mg vs. 190 mg dexamethasone equivalents). These favorable findings did not have a deleterious impact on outcomes and efficacy with similar overall response rate, progression‐free survival, and overall survival with both toxicity management approaches.
- 20 September 2021
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 39 (27) , 3034-3043
Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial
PURPOSE: Although the majority of patients with relapsed or refractory large B-cell lymphoma respond to axicabtagene ciloleucel (axi-cel), only a minority of patients have durable remissions. This prospective multicenter study explored the prognostic value of circulating tumor DNA (ctDNA) before and after standard-of-care axi-cel for predicting patient outcomes. METHODS: Lymphoma-specific variable, diversity, and joining gene segments (VDJ) clonotype ctDNA sequences were frequently monitored via next-generation sequencing from the time of starting lymphodepleting chemotherapy until progression or 1 year after axi-cel infusion. We assessed the prognostic value of ctDNA to predict outcomes and axi-cel–related toxicity. RESULTS: A tumor clonotype was successfully detected in 69 of 72 (96%) enrolled patients. Higher pretreatment ctDNA concentrations were associated with progression after axi-cel infusion and developing cytokine release syndrome and/or immune effector cell–associated neurotoxicity syndrome. Twenty-three of 33 (70%) durably responding patients versus 4 of 31 (13%) progressing patients demonstrated nondetectable ctDNA 1 week after axi-cel infusion ( P < .0001). At day 28, patients with detectable ctDNA compared with those with undetectable ctDNA had a median progression-free survival and OS of 3 months versus not reached ( P < .0001) and 19 months versus not reached ( P = .0080), respectively. In patients with a radiographic partial response or stable disease on day 28, 1 of 10 patients with concurrently undetectable ctDNA relapsed; by contrast, 15 of 17 patients with concurrently detectable ctDNA relapsed ( P = .0001). ctDNA was detected at or before radiographic relapse in 29 of 30 (94%) patients. All durably responding patients had undetectable ctDNA at or before 3 months after axi-cel infusion. CONCLUSION: Noninvasive ctDNA assessments can risk stratify and predict outcomes of patients undergoing axi-cel for the treatment of large B-cell lymphoma. These results provide a rationale for designing ctDNA-based risk-adaptive chimeric antigen receptor T-cell clinical trials.
- 20 September 2021
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 39 (27) , 3034-3043
Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial
PURPOSE: Although the majority of patients with relapsed or refractory large B-cell lymphoma respond to axicabtagene ciloleucel (axi-cel), only a minority of patients have durable remissions. This prospective multicenter study explored the prognostic value of circulating tumor DNA (ctDNA) before and after standard-of-care axi-cel for predicting patient outcomes. METHODS: Lymphoma-specific variable, diversity, and joining gene segments (VDJ) clonotype ctDNA sequences were frequently monitored via next-generation sequencing from the time of starting lymphodepleting chemotherapy until progression or 1 year after axi-cel infusion. We assessed the prognostic value of ctDNA to predict outcomes and axi-cel–related toxicity. RESULTS: A tumor clonotype was successfully detected in 69 of 72 (96%) enrolled patients. Higher pretreatment ctDNA concentrations were associated with progression after axi-cel infusion and developing cytokine release syndrome and/or immune effector cell–associated neurotoxicity syndrome. Twenty-three of 33 (70%) durably responding patients versus 4 of 31 (13%) progressing patients demonstrated nondetectable ctDNA 1 week after axi-cel infusion ( P < .0001). At day 28, patients with detectable ctDNA compared with those with undetectable ctDNA had a median progression-free survival and OS of 3 months versus not reached ( P < .0001) and 19 months versus not reached ( P = .0080), respectively. In patients with a radiographic partial response or stable disease on day 28, 1 of 10 patients with concurrently undetectable ctDNA relapsed; by contrast, 15 of 17 patients with concurrently detectable ctDNA relapsed ( P = .0001). ctDNA was detected at or before radiographic relapse in 29 of 30 (94%) patients. All durably responding patients had undetectable ctDNA at or before 3 months after axi-cel infusion. CONCLUSION: Noninvasive ctDNA assessments can risk stratify and predict outcomes of patients undergoing axi-cel for the treatment of large B-cell lymphoma. These results provide a rationale for designing ctDNA-based risk-adaptive chimeric antigen receptor T-cell clinical trials.
- 9 September 2021
- Published by Wiley in British Journal of Haematology
- Vol. 195 (3) , 405-412
The impact of bridging therapy prior to CD19‐directed chimeric antigen receptor T‐cell therapy in patients with large B‐cell lymphoma
Summary: In the relapsed/refractory setting for treatment of large B‐cell lymphoma (LBCL), chimeric antigen receptor T‐cell (CAR‐T) therapy has emerged as an effective treatment modality. Patients often have aggressive disease that requires prompt treatment in the form of bridging therapy (BT) for disease stabilisation while CAR‐T cells are manufactured. Patients (n = 75) undergoing CAR‐T therapy infusion for LBCL at our institution were identified. A total of 52 (69·3%) received BT and 23 (30·7%) received no BT (NBT). BT modalities included systemic BT (SBT) in 28 patients, radiation BT (RBT) in 14, and high‐dose steroid BT (HDS) in 10. There was no difference in incidence of cytokine release syndrome or immune effector cell‐associated neurotoxicity syndrome between BT and NBT (P = 0·18 and P = 0·53 respectively). Prolonged cytopenias at Day 180 were more common in BT than NBT (50% vs. 13·3%, P = 0·04). The SBT and RBT subgroups had more cytopenias at Day 180 compared to the HDS and NBT subgroups (58·3% and 57·1% vs. 20% and 13·3% respectively, P = 0·04). Disease response at last follow‐up, progression‐free survival and overall survival were similar between BT, NBT, and BT subgroups. In summary, BT can be safely considered in patients undergoing CAR‐T therapy. However, those undergoing BT with SBT or RBT are at higher risk of prolonged cytopenias after CAR‐T therapy.
- 9 September 2021
- Published by Wiley in British Journal of Haematology
- Vol. 195 (3) , 405-412
The impact of bridging therapy prior to CD19‐directed chimeric antigen receptor T‐cell therapy in patients with large B‐cell lymphoma
Summary: In the relapsed/refractory setting for treatment of large B‐cell lymphoma (LBCL), chimeric antigen receptor T‐cell (CAR‐T) therapy has emerged as an effective treatment modality. Patients often have aggressive disease that requires prompt treatment in the form of bridging therapy (BT) for disease stabilisation while CAR‐T cells are manufactured. Patients (n = 75) undergoing CAR‐T therapy infusion for LBCL at our institution were identified. A total of 52 (69·3%) received BT and 23 (30·7%) received no BT (NBT). BT modalities included systemic BT (SBT) in 28 patients, radiation BT (RBT) in 14, and high‐dose steroid BT (HDS) in 10. There was no difference in incidence of cytokine release syndrome or immune effector cell‐associated neurotoxicity syndrome between BT and NBT (P = 0·18 and P = 0·53 respectively). Prolonged cytopenias at Day 180 were more common in BT than NBT (50% vs. 13·3%, P = 0·04). The SBT and RBT subgroups had more cytopenias at Day 180 compared to the HDS and NBT subgroups (58·3% and 57·1% vs. 20% and 13·3% respectively, P = 0·04). Disease response at last follow‐up, progression‐free survival and overall survival were similar between BT, NBT, and BT subgroups. In summary, BT can be safely considered in patients undergoing CAR‐T therapy. However, those undergoing BT with SBT or RBT are at higher risk of prolonged cytopenias after CAR‐T therapy.
- Open Access
- 10 November 2020
- Published by Wiley in British Journal of Haematology
- Vol. 192 (1) , 212-216
Chimeric antigen receptor T‐cell therapy after allogeneic stem cell transplant for relapsed/refractory large B‐cell lymphoma
- 10 November 2020
- Published by Wiley in British Journal of Haematology
- Vol. 192 (1) , 212-216
Open AccessChimeric antigen receptor T‐cell therapy after allogeneic stem cell transplant for relapsed/refractory large B‐cell lymphoma
- Open Access
- 31 March 2020
- Published by Wiley in American Journal of Hematology
- Vol. 95 (6) , E146-E148
Severe dysautonomia as a manifestation of neurotoxicity after CAR‐T cell therapy for diffuse large B‐cell lymphoma
- 31 March 2020
- Published by Wiley in American Journal of Hematology
- Vol. 95 (6) , E146-E148
Open AccessSevere dysautonomia as a manifestation of neurotoxicity after CAR‐T cell therapy for diffuse large B‐cell lymphoma
- 1 December 2019
- Published by Elsevier in The American Journal of Medicine
- Vol. 132 (12) , e852-e853
Rejection, but in a Different Direction: Graft-Versus-Host Disease after Solid Organ Transplantation Mimicking an Infection
- 1 December 2019
- Published by Elsevier in The American Journal of Medicine
- Vol. 132 (12) , e852-e853
Rejection, but in a Different Direction: Graft-Versus-Host Disease after Solid Organ Transplantation Mimicking an Infection
- Open Access
- 24 July 2019
- Published by Wiley in American Journal of Hematology
- Vol. 94 (10) , E273-E275
Rapid relapse of large B‐cell lymphoma after CD19 directed CAR‐T‐cell therapy due to CD‐19 antigen loss
- 24 July 2019
- Published by Wiley in American Journal of Hematology
- Vol. 94 (10) , E273-E275
Open AccessRapid relapse of large B‐cell lymphoma after CD19 directed CAR‐T‐cell therapy due to CD‐19 antigen loss